Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Special Feature Articles - Most Recent
    • Special Features
    • Colloquia
    • Collected Articles
    • PNAS Classics
    • List of Issues
  • Front Matter
    • Front Matter Portal
    • Journal Club
  • News
    • For the Press
    • This Week In PNAS
    • PNAS in the News
  • Podcasts
  • Authors
    • Information for Authors
    • Editorial and Journal Policies
    • Submission Procedures
    • Fees and Licenses
  • Submit
  • Submit
  • About
    • Editorial Board
    • PNAS Staff
    • FAQ
    • Accessibility Statement
    • Rights and Permissions
    • Site Map
  • Contact
  • Journal Club
  • Subscribe
    • Subscription Rates
    • Subscriptions FAQ
    • Open Access
    • Recommend PNAS to Your Librarian

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Home
Home
  • Log in
  • My Cart

Advanced Search

  • Home
  • Articles
    • Current
    • Special Feature Articles - Most Recent
    • Special Features
    • Colloquia
    • Collected Articles
    • PNAS Classics
    • List of Issues
  • Front Matter
    • Front Matter Portal
    • Journal Club
  • News
    • For the Press
    • This Week In PNAS
    • PNAS in the News
  • Podcasts
  • Authors
    • Information for Authors
    • Editorial and Journal Policies
    • Submission Procedures
    • Fees and Licenses
  • Submit
Commentary

Nitric oxide and cisplatin resistance: NO easy answers

John J. Turchi
  1. Department of Medicine and Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indiana University Cancer Research Institute, 1044 West Walnut Street, R4-202, Indianapolis, IN 46202

See allHide authors and affiliations

PNAS March 21, 2006 103 (12) 4337-4338; https://doi.org/10.1073/pnas.0601001103
John J. Turchi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jturchi@iupui.edu
  • Article
  • Figures & SI
  • Info & Metrics
  • PDF
Loading

Cisplatin is one of the most widely used chemotherapeutic drugs for treating cancer. Initially, platinum-based therapies are very effective in treating a wide array of cancers; however, recurrence and resistance remain the major limitation to curative therapies (1). Although cisplatin resistance is clearly multifactorial in nature, increased levels of cellular thiols are often associated with the cisplatin-resistant phenotype (2). Cellular thiols, which include glutathione (GSH), can sequester cisplatin, leading to a reduction in the levels of cisplatin–DNA damage. DNA is the therapeutic target of cisplatin, and efficacy is a function of cisplatin–DNA adducts inhibiting DNA replication and transcription, ultimately resulting in apoptosis. Reduced efficacy of the cisplatin is often observed in cells with increased GSH levels. Modulating the levels of intracellular thiols has been demonstrated to influence cisplatin cytotoxicity in numerous studies (3). In a report by Bratasz et al. (4) in a recent issue of PNAS, the authors exploited GSH overexpression using a nitric oxide (NO)-prodrug in a cisplatin-resistant ovarian cancer model to potentially counteract and target cisplatin-resistant cells.

NO has proven to be an important component in numerous signaling pathways and elicits a wide variety of biological effects (5). The regulation and cellular effects of both endogenous and exogenous NO production have been studied in great detail. The development of NO-donating small-molecule prodrugs has resulted in the detailed characterization of the NO response in many aspects of cardiovascular biology (6).

More recently, NO and NO-prodrugs have been assessed for activity in the prevention and treatment of cancer (Fig. 1). Varied results have been reported in numerous cell cancer models. In general, when observed, the cytostatic activity of NO-donating compounds is attributed to the NO-moiety or a function of the metabolism of the prodrug. These conclusions are based on the lack of cytostatic activity with the parental compounds. Perhaps more relevant to the single-agent therapy is the potential of NO and NO-prodrugs to synergize with traditional chemotherapeutic agents in treating cancer. One study used tissue culture media saturated with NO gas and demonstrated that sensitivity to the cytotoxic activity of cisplatin was increased dramatically and that the effect could be mimicked with a subset of chemical NO donors (7). Interestingly, no toxicity was associated with any of the NO treatments in the absence of cisplatin, and the authors discounted intracellular thiols as mediating the cisplatin-sensitization effect. More recent analysis of NO-prodrugs specifically designed to interact with glutathione S-transferase (GST) also demonstrated synergism with cisplatin, an effect attributed to increased cellular accumulation of cisplatin and potentially activation of the mitogen-activated protein kinase (MAPK) pathway (8). The effect of NO on MAPK was originally determined in vascular smooth muscle cells (9) and more recently in colon cancer cells where cytostatic activity was demonstrated to involve MAPK (10). Consistent with the above analyses, a series of NO-donating aspirin derivatives revealed that the aspirin or nonsteroidal antiinflammatory drug released could not account for the cytostatic activity (11).

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Interplay of factors involved in cisplatin resistance and the potential roles of NO. Cisplatin-dependent cytotoxicity is a function of the degree of DNA damage induced and the efficiency of repairing the cisplatin–DNA lesions. NO and NO-prodrugs induce numerous changes that can ultimately influence the cellular sensitivity to cisplatin. Stimulatory or enhancing interactions are depicted by the green arrows, and inhibitory effects are indicated by the red, blunted arrows. HBA, 3-hydroxybenzylalcohol; HBN, 3-(nitrooxymethyl)phenol.

Considering the numerous and conflicting reports on the effect of NO and NO-prodrugs on pathways relevant to cancer, the bioactivation of these compounds becomes critical. Some of the variation in activity can be attributed to the rate and duration of NO production as well as the individual cell type being studied. The NO-aspirin derivatives are perhaps the most well studied where slow release of NO by NCX-4016 and other NO-prodrug derivatives appears to be more effective in eliciting the desired responses for cancer chemotherapy. Metabolism of NO-aspirin derivatives typically involves cleavage of the ester linker via a nonspecific esterase to release the aspirin derivative and a nitrooxymethyl derivative (HBN). The NO-containing HBN can then be metabolized further by GST to form an HBA–GSH adduct with concomitant release of NO 3 (12). In addition, other detoxification pathways likely contribute to the metabolism of these agents. The end result of this activation and metabolism is the generation of NO and salicylic acid, and the use of reduction potential via the GST/GSH pathway, each of which could potentially influence cell proliferation and sensitivity to chemotherapeutic agents. These pathways and interactions are further complicated by the recent demonstration that different isomers of NO-aspirin differ in bioactivation, cytostatic, apoptotic, and chemopreventative activity (13, 14).

The study by Bratasz et al. (4) provides evidence that an NO-donating derivative of aspirin, NCX-4016, may be useful in overcoming the cisplatin-resistance phenomenon associated with glutathione metabolism, often observed in recurrent ovarian cancer. There is substantial evidence that intracellular thiols contribute to the bioactivation of NO-releasing compounds (8, 12, 15). Thus, increased NO production would be expected in cisplatin-resistant ovarian cancer cells that have increased GST activity and GSH levels. The NO-donating compound could potentially be more effective as a standalone cytotoxic agent for cisplatin-resistant cancers. The second mechanism involving intracellular thiols postulates the NO-releasing agent competing with cisplatin for the intracellular thiols. This mechanism would be expected to reduce cisplatin–GSH sequestration and increase cisplatin–DNA adducts, thereby increasing the efficacy of cisplatin in these resistant cancers. This line of thought would predict that NCX-4016 should display a synergistic interaction with cisplatin. The results obtained by Bratasz et al. (4) are in fact consistent with these pathways and interactions. The demonstration that NO-donating compounds induce oxidative stress and initiate apoptosis (16) suggests that GSH overexpression would hinder the activity of NCX-4016. Again, NO-dependent inhibition of caspase activity was shown to inhibit apoptosis (17). However, reports that NO inhibits nucleotide excision repair (18), the pathway responsible for repair of cisplatin–DNA intrastrand lesions (19), suggest that NO synergy with cisplatin could be independent of GSH as was demonstrated in earlier studies. Clearly, the cellular response to both NO and cisplatin is extremely complex. Although definitive determination of the mechanisms involved in NO chemosensitization remains, this work opens the door for more detailed studies of combined treatment regimens. Only then can the full potential of the NO-prodrug approach be realized for reversal of the continuing problem of clinical resistance to cisplatin.

Footnotes

  • *E-mail: jturchi{at}iupui.edu
  • Author contributions: J.J.T. wrote the paper.

  • Conflict of interest statement: No conflicts declared.

  • See companion article on page 3914 in issue 10 of volume 103.

  • © 2006 by The National Academy of Sciences of the USA

References

  1. ↵
    1. Muggia F. M. ,
    2. Fojo T.
    (2004) J. Chemother 16:77–82, pmid:15688617.
    OpenUrlPubMed
  2. ↵
    1. Schroder C. P. ,
    2. Godwin A. K. ,
    3. O’Dwyer P. J. ,
    4. Tew K. D. ,
    5. Hamilton T. C. ,
    6. Ozols R. F.
    (1996) Cancer Invest 14:158–168, pmid:8597901.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Townsend D. M. ,
    2. Findlay V. L. ,
    3. Tew K. D.
    (2005) Gluthione Transferases Gamma-Glutamyl Transpeptidases 401:287–307.
    OpenUrlCrossRef
  4. ↵
    1. Bratasz A. ,
    2. Weir N. M. ,
    3. Parinandi N. L. ,
    4. Zweier J. L. ,
    5. Sridhar R. ,
    6. Ignarro L. J. ,
    7. Kuppusamy P.
    (2006) Proc. Natl. Acad. Sci. USA 103:3914–3919, pmid:16497833.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Ignarro L. J.
    (2002) J. Physiol. Pharmacol 53:503–514, pmid:12512688.
    OpenUrlPubMed
  6. ↵
    1. Ignarro L. J. ,
    2. Napoli C. ,
    3. Loscalzo J.
    (2002) Circ. Res 90:21–28, pmid:11786514.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Wink D. A. ,
    2. Cook J. A. ,
    3. Christodoulou D. ,
    4. Krishna M. C. ,
    5. Pacelli R. ,
    6. Kim S. ,
    7. DeGraff W. ,
    8. Gamson J. ,
    9. Vodovotz Y. ,
    10. Russo A. ,
    11. et al.
    (1997) Nitric Oxide Biol. Chem 1:88–94.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Liu J. ,
    2. Li C. X. ,
    3. Qu W. ,
    4. Leslie E. ,
    5. Bonifant C. L. ,
    6. Buzard G. S. ,
    7. Saavedra J. E. ,
    8. Keefer L. K. ,
    9. Waalkes M. P.
    (2004) Mol. Cancer Ther 3:709–714, pmid:15210857.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Bauer P. M. ,
    2. Buga G. M. ,
    3. Ignarro L. J.
    (2001) Proc. Natl. Acad. Sci. USA 98:12802–12807, pmid:11592976.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Hundley T. R. ,
    2. Rigas B.
    (2006) J. Pharmacol. Exp. Ther 316:25–34, pmid:16169935.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Yeh R. K. ,
    2. Chen J. ,
    3. Williams J. L. ,
    4. Baluch M. ,
    5. Hundley T. R. ,
    6. Rosenbaum R. E. ,
    7. Kalala S. ,
    8. Traganos F. ,
    9. Benardini F. ,
    10. Del Soldato P. ,
    11. et al.
    (2004) Biochem. Pharmacol 67:2197–2205, pmid:15163551.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Carini M. ,
    2. Aldini G. ,
    3. Orioli M. ,
    4. Facino R. M.
    (2002) J. Pharm. Biomed. Anal 29:1061–1071, pmid:12110391.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Gao J. J. ,
    2. Kashfi K. ,
    3. Rigas B.
    (2005) J. Pharmacol. Exp. Ther 312:989–997, pmid:15528452.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Kashfi K. ,
    2. Borgo S. ,
    3. Williams J. L. ,
    4. Chen J. ,
    5. Gao J. J. ,
    6. Glekas A. ,
    7. Benedini F. ,
    8. Del Soldato P. ,
    9. Rigas B.
    (2005) J. Pharmacol. Exp. Ther 312:978–988, pmid:15528453.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Williams J. L. ,
    2. Nath N. ,
    3. Chen J. ,
    4. Hundley T. R. ,
    5. Gao J. J. ,
    6. Kopelovich L. ,
    7. Kashfi K. ,
    8. Rigas B.
    (2003) Cancer Res 63:7613–7618, pmid:14633677.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Gao J. J. ,
    2. Liu X. P. ,
    3. Rigas B.
    (2005) Proc. Natl. Acad. Sci. USA 102:17207–17212, pmid:16282376.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Melino G. ,
    2. Bernassola F. ,
    3. Knight R. A. ,
    4. Corasaniti M. T. ,
    5. Nistico G. ,
    6. Finazzi-Agro A.
    (1997) Nature 388:432–433, pmid:9242400.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Chien Y. H. ,
    2. Bau D. T. ,
    3. Jan K. Y.
    (2004) Free Radical Biol. Med 36:1011–1017, pmid:15059641.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Turchi J. J. ,
    2. Henkels K. M. ,
    3. Hermanson I. L. ,
    4. Patrick S. M.
    (1999) J. Inorg. Biochem 77:83–87, pmid:10626358.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Article Alerts
Email Article

Thank you for your interest in spreading the word on PNAS.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Nitric oxide and cisplatin resistance: NO easy answers
(Your Name) has sent you a message from PNAS
(Your Name) thought you would like to see the PNAS web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Nitric oxide and cisplatin resistance: NO easy answers
John J. Turchi
Proceedings of the National Academy of Sciences Mar 2006, 103 (12) 4337-4338; DOI: 10.1073/pnas.0601001103

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Nitric oxide and cisplatin resistance: NO easy answers
John J. Turchi
Proceedings of the National Academy of Sciences Mar 2006, 103 (12) 4337-4338; DOI: 10.1073/pnas.0601001103
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Mendeley logo Mendeley

Related Article

  • Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin
    - Feb 23, 2006
Proceedings of the National Academy of Sciences of the United States of America: 103 (12)
Table of Contents

Submit

Sign up for Article Alerts

Jump to section

  • Article
    • Footnotes
    • References
  • Figures & SI
  • Info & Metrics
  • PDF

You May Also be Interested in

Water from a faucet fills a glass.
News Feature: How “forever chemicals” might impair the immune system
Researchers are exploring whether these ubiquitous fluorinated molecules might worsen infections or hamper vaccine effectiveness.
Image credit: Shutterstock/Dmitry Naumov.
Reflection of clouds in the still waters of Mono Lake in California.
Inner Workings: Making headway with the mysteries of life’s origins
Recent experiments and simulations are starting to answer some fundamental questions about how life came to be.
Image credit: Shutterstock/Radoslaw Lecyk.
Cave in coastal Kenya with tree growing in the middle.
Journal Club: Small, sharp blades mark shift from Middle to Later Stone Age in coastal Kenya
Archaeologists have long tried to define the transition between the two time periods.
Image credit: Ceri Shipton.
Illustration of groups of people chatting
Exploring the length of human conversations
Adam Mastroianni and Daniel Gilbert explore why conversations almost never end when people want them to.
Listen
Past PodcastsSubscribe
Panda bear hanging in a tree
How horse manure helps giant pandas tolerate cold
A study finds that giant pandas roll in horse manure to increase their cold tolerance.
Image credit: Fuwen Wei.

Similar Articles

Site Logo
Powered by HighWire
  • Submit Manuscript
  • Twitter
  • Facebook
  • RSS Feeds
  • Email Alerts

Articles

  • Current Issue
  • Special Feature Articles – Most Recent
  • List of Issues

PNAS Portals

  • Anthropology
  • Chemistry
  • Classics
  • Front Matter
  • Physics
  • Sustainability Science
  • Teaching Resources

Information

  • Authors
  • Editorial Board
  • Reviewers
  • Subscribers
  • Librarians
  • Press
  • Cozzarelli Prize
  • Site Map
  • PNAS Updates
  • FAQs
  • Accessibility Statement
  • Rights & Permissions
  • About
  • Contact

Feedback    Privacy/Legal

Copyright © 2021 National Academy of Sciences. Online ISSN 1091-6490